ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1634834
This article is part of the Research TopicAdvances in Esophageal Cancer: Treatment Updates and Future ChallengesView all 16 articles
The Impact of Immunotherapy on the Prognosis of Small Cell Carcinoma of the Esophagus: A Propensity Score-Matched Analysis of a Retrospective Study
Provisionally accepted- 1Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- 2Shandong University, Jinan, China
- 3Shandong University, Shandong Provincial Hospital, Jinan, China
- 4Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- 5Department of Radiation Oncology, Affiliated Hospital of Shandong University of Chinese Medicine, Jinan, China
- 6Affiliated Hospital of Southwest Medical University, Luzhou, China
- 7Southwest Medical University, Luzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Small cell carcinoma of the esophagus (SCCE) is a rare neuroendocrine malignancy with no standardized treatment regimen. This study aims to evaluate the impact of immunotherapy on the prognostic survival outcomes of patients with SCCE. Methods: A retrospective analysis was conducted on 83 SCCE patients treated at the Provincial Hospital of Shandong First Medical University and the Cancer Hospital of Shandong First Medical University from January 2020 to June 2024. Propensity score matching (PSM) was applied to minimize potential biases between patients who received combination immunotherapy and those who did not. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were assessed using the Kaplan-Meier method, while univariate and multivariate analyses were performed using the Cox proportional hazards model. Results: Among the 83 patients included, 33 received combination immunotherapy and 50 did not. Prior to PSM, clinicopathological comparisons revealed that tumor size was significantly larger in the non-immunotherapy group (P = 0.032), and the immunotherapy group had more advanced N stages (P = 0.015). After 1:1 PSM, 20 matched pairs were analyzed. The immunotherapy group demonstrated a significantly longer OS compared to the non-immunotherapy group (22 months vs. 13 months, P = 0.0165), though PFS differences were not statistically significant (9 months vs. 7 months, P > 0.05). Univariate and multivariate analyses identified treatment methods (P=0.039) as independent prognostic factors for OS. Survival rate analysis showed that patients in the immunotherapy group achieved superior six-month (97.0% vs. 83.7%), one-year (78.9% vs. 56.5%), and two-year (22.1% vs. 10.4%) survival rates compared to the non-immunotherapy group. Conclusions:This study demonstrates that combination immunotherapy significantly improves overall survival in SCCE patients and represents an effective treatment strategy for this rare malignancy.
Keywords: Immunotherapy, Small cell carcinoma of the esophagus, Propensity score matching, prognosis, overall survival, Progression free survival
Received: 25 May 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Wang, Liu, Yang, Zhu, Zhou, Li, Feng and Jing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bin Feng, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
Wang Jing, Department of Radiation Oncology, Affiliated Hospital of Shandong University of Chinese Medicine, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.